Učitavanje...
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have...
Spremljeno u:
| Izdano u: | Blood |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510786/ https://ncbi.nlm.nih.gov/pubmed/28500170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-742288 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|